Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
RESEARCH TOOLSreports
Holding TCRT?
Track your performance easily
TCRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.95 - $32.87
Previous Close$2.1
Volume18.46K
Average Volume (3M)20.02K
Market Cap
$3.36M
Enterprise Value$899.63K
Total Cash (Recent Filing)$2.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.95
Shares Outstanding1,601,252
10 Day Avg. Volume15,161
30 Day Avg. Volume20,025
Standard Deviation0.37
R-Squared0.00475
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.03
Price to Sales (P/S)560.44
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue149.94
Enterprise Value/Gross Profit179.93
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alaunos Therapeutics News
PremiumCompany Announcements
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
PremiumCompany Announcements
Alaunos Therapeutics Announces Executive Financial Leadership Changes
PremiumCompany Announcements
Alaunos Therapeutics Regains Nasdaq Listing Compliance
PremiumCompany Announcements
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TCRT FAQ
What was Alaunos Therapeutics’s price range in the past 12 months?
Alaunos Therapeutics lowest stock price was $1.95 and its highest was $32.87 in the past 12 months.
What is Alaunos Therapeutics’s market cap?
Currently, no data Available
When is Alaunos Therapeutics’s upcoming earnings report date?
Alaunos Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is 6 days ago.
How were Alaunos Therapeutics’s earnings last quarter?
Alaunos Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.705.
Is Alaunos Therapeutics overvalued?
According to Wall Street analysts Alaunos Therapeutics’s price is currently Overvalued.
Does Alaunos Therapeutics pay dividends?
Alaunos Therapeutics does not currently pay dividends.
What is Alaunos Therapeutics’s EPS estimate?
Alaunos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alaunos Therapeutics have?
Alaunos Therapeutics has 1,601,252 shares outstanding.
What happened to Alaunos Therapeutics’s price movement after its last earnings report?
Alaunos Therapeutics reported an EPS of -$0.705 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.481%.
Which hedge fund is a major shareholder of Alaunos Therapeutics?
Among the largest hedge funds holding Alaunos Therapeutics’s share is Discovery Capital Management, LLC. It holds Alaunos Therapeutics’s shares valued at N/A.
---
Alaunos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 26.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.24%
12-Months-Change
Fundamentals
Return on Equity
-150.51%
Trailing 12-Months
Asset Growth
-83.25%
Trailing 12-Months
Company Description
Alaunos Therapeutics
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
---
TCRT Earnings Call
Q1 2023
0:00 / 0:00
---
TCRT Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Cellectar Biosciences
―
Marker Therapeutics
―
Oncternal Therapeutics
―
---